dabrafenib + panitumumab

dabrafenib + panitumumab is an investigational combination therapy studied for the treatment of metastatic colorectal cancer (CRC) with the BRAF V600E mutation. Dabrafenib is a small molecule inhibitor targeting BRAF V600E, which blocks downstream signaling in the MAPK pathway, thereby inhibiting cancer cell proliferation. Panitumumab is a monoclonal antibody targeting the extracellular domain of the epidermal growth factor receptor (EGFR), blocking ligand-induced activation and subsequent signaling. Together, the combination aims to overcome adaptive resistance mechanisms—specifically, feedback reactivation of MAPK signaling through EGFR—seen with BRAF inhibitor monotherapy in CRC[1][4][6]. Clinical trials tested full monotherapy doses (dabrafenib 150 mg orally twice daily and panitumumab 6 mg/kg IV every 2 weeks) and showed manageable safety with common toxicities including mild-moderate dermatitis acneiform, nausea, fatigue, and diarrhea[1][6]. Confirmed objective response rate was 10% in heavily pre-treated patient cohorts[4][6].

Brand names

Tafinlar (dabrafenib)Vectibix (panitumumab)

Other names

dabrafenib + panitumumab